Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Infographic: Are data blind spots putting your launch at risk?

July 16, 2026 |  

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize opportunities, and optimize commercial strategy.​

InConcert™ brings together omnichannel, field, clinical, and predictive insights in a single decision-making environment – helping commercial teams make smarter, faster decisions backed by Intelligent Commercialization™.

- PMLiVE

Discover how InConcert™ supports commercial launch planning​

If you’re looking for a quick, easy-to-understand overview of InConcert™, this one-page guide is the perfect place to start.​

In just a few minutes, you’ll discover:​

  • The commercial challenge the solution is designed to solve.​
  • How it enables intelligent launch planning.​
  • The four intelligence capabilities that power InConcert™.​
  • The value it delivers for commercial and launch teams.​
  • How it helps organizations make more informed launch decisions.​

Whether you’re exploring InConcert™ for the first time or introducing it to key stakeholders, this concise overview explains everything you need to know – all on a single page.

Download now. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Webinar: The Brazil Conundrum

Conducting research in one of the world’s largest pharma markets

Webinar: Demand calibration: What’s inside the black box?

The process of demand calibration of preference share (down-weighting) is often a proprietary “black box” technique, which can mean that the client is unsure how the calibrated figure has been…

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

5 years on from the Brazilian Generics Drugs Act, is there still an opportunity for branded originator drugs?

Published in Eye for Pharma 10 November by Marc Yates

Pegasus picks up “Specialist Consultancy of the Year” at the PRCA Awards 2014

Pegasus, the UK’s leading independent health communications consultancy, picked up the “Specialist Consultancy of the Year” award at the PRCA Awards 2014.

Pegasus supports unique theatrical performance as part of the 9th UK Dementia Congress

Brighton-based Pegasus, the UK’s leading independent health communications consultancy, is pleased to be supporting Naomi’s Flight – a bold and unique theatrical performance tour that highlights the impact of dementia…

It’s a hat trick for Pegasus!

Pegasus scoops the much-coveted “Consultancy of the Year” prize at the PR Week Awards 2014

Exploring MINT: Part 4 – Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in…